Skip to main content
University of California San Francisco
About UCSF
Search UCSF
UCSF Medical Center
Radiology
Search
About
People
Opportunity and Outreach
Wellbeing and Professional Climate
Make a Gift
Contact Us
Patient Care
For Health Professionals
For Patients
Services Offered
Clinical Divisions
Patient Safety
Education
Diagnostic Radiology Residency
Integrated IR Residency
Independent IR Residency
NucMed Residency & Fellowship
Fellowships
T32 Program
Medical Student Education
Master of Science in Biomedical Imaging (MSBI)
Continuing Medical Education
The Margulis Society for Alumni
Distinguished Lecture Series
Research
Research Directory
Imaging Research Symposium
Research Conference
UCSF Radiology at RSNA
Core Services
Academic Affairs
Academic Recruitment
Academic Advancement
Development & Courses
Faculty Mentoring
Faculty Thrive Guide
Celebrating Faculty & Alumni
Department Committees
FAQs
Locations
News
Events
Honors and Awards
Department Publications
Breadcrumb
Home
/
About
/
People
/
Michael Evans, PhD
/
Publications
Michael Evans, PhD's Publications
Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies.
Imaging the Granzyme Mediated Host Immune Response to Viral and Bacterial Pathogens In Vivo Using Positron Emission Tomography.
Millimeter-scale radioluminescent power for electronic sensors.
Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [ 18 F]FDG yield potent sensors of living bacteria in vivo.
Chemoenzymatic Syntheses of Fluorine-18-Labeled Disaccharides from [18F] FDG Yield Potent Sensors of Living Bacteria In Vivo.
Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects.
Dosimetry Reconstruction in Radiopharmaceutical Therapy Using a Sparse Network of External ?-Sensors.
Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy.
Preclinical evaluation of theranostic strategy using nanoplatform and transferrin to target hyperactivity of cMYC in the context of non-small cell lung cancer.
SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy.
Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
Avalanche Photodiode-Based ?-Photon Scintillation Detectors for Personalized Dosimetry in Targeted Radionuclide Therapy.
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex.
Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.
Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand.
In Vivo Profiling with 18F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions.
P-125 Pharmacokinetic preclinical evaluation of radioligation strategies impact on antibody fragment targeting PD-L1.
Personalized Lu177 Theranostic Dosimetry Using a Single Beta-Particle In Vivo Microdosimeter.
Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology.
Switchable assembly and function of antibody complexes in vivo using a small molecule.
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Feasibility study of gallium-68 citrate PET as a bone-tropic imaging biomarker in mCRPC.
In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET.
Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats.
Quantitative Tissue Pharmacokinetics and EPR Effect of AGuIX Nanoparticles: A Multimodal Imaging Study in an Orthotopic Glioblastoma Rat Model and Healthy Macaque.
Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography.
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
Arabinofuranose-derived positron-emission tomography radiotracers for detection of pathogenic microorganisms.
Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies.
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm.
Synthesis and Screening of α-Xylosides in Human Glioblastoma Cells.
The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)-11C-YJH08 PET.
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.
Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches.
Abstract 550: Tumor-conditional anti-CTLA-4 uncouples anti-tumor efficacy from immunotherapy-related toxicity.
Enzymatically Catalyzed Radiofluorination of Biomolecules.
Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography.
Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling.
Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4.
Abstract 3694: Measuring oncogene signaling with transferrin-based PET: From bench to bedside.
AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine.
Development of a stress response therapy targeting aggressive prostate cancer.
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
Measuring glucocorticoid receptor expression in vivo with PET.
PET imaging of tumor PD-L1 expression with 89Zr-labeled anti-PD-L1 antibodies.
Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR.
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins.
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Abstract A25: Sensing stress in cancer: a novel therapy targeting protein synthesis through the unfolded protein response in prostate cancer development.
Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen.
Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.
Imaging PD-L1 Expression with ImmunoPET.
Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.
Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer.
Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
11C-Ascorbic and 11C-dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer.
A Reactivity-Based [18F]FDG Probe for In Vivo Formaldehyde Imaging Using Positron Emission Tomography
A reactivity-based [18F]FDG probe for in vivo formaldehyde imaging using positron emission tomography.
Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.
Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin.
Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase.
Synthesis and Characterization of (89)Zr-Labeled Ultrasmall Nanoparticles.
[(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography.
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.
Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.
Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography.
859 Evaluating the impact of adulthood metabolic disorders on prostatic cancer etiology with early-in-life risk factors.
89Zr-MSTP2109A, A Novel Antibody Based Radiotracer to Evaluate and Guide the Clinical Translation of Antibody-Drug Conjugates Targeting STEAP1.
Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries.
Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.
Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.
Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Overcoming mutation-based resistance to antiandrogens with rational drug design.
Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.
Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
Abstract IA22: Molecular Imaging of androgen receptor signalling in CRPC.
Annotating MYC status with 89Zr-transferrin imaging.
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
Imaging tumor burden in the brain with 89Zr-transferrin.
Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.
Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.
Präklinische Evaluation eines neuartigen Therapieansatzes im malignen Melanom mittels F-18 FDG PET und Fluorescence Molecular Tomography (FMT).
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.
Abstract B207: Prostate specific membrane antigen is a diagnostic marker of response to allosteric androgen receptor inhibition.
Polyanionic gallium hydrides from AlB2-type precursors AeGaE (Ae = Ca, Sr, Ba; E = Si, Ge, Sn).
Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides.
Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines.
Mechanism-Based Profiling of Enzyme Families.
Mechanism-based profiling of enzyme families.
Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling.
